Information on research, events, activities, and news from the T1D community across Canada.
Now that 2019 has drawn to a close, we want to take a moment and extend our sincere thanks and appreciation for your support of our efforts in finding cures for type 1 diabetes (T1D) and improving the lives of the more than 300,000 Canadians and their families touched by this disease.
Dr. Suheda Erener is currently investigating whether micro-RNAs – a family of single-stranded molecules which are key regulators of gene expression and beta cell function – can predict the development of T1D.
Upon a recent appointment with her endocrinologist, Meagan learned she would need to start with a new insulin pump that would give her the best control possible, but would also result on relying on a CGM — an expense she wasn’t prepared for, despite being a working professional with priv...
JDRF Canada partners with CIHR in new funding opportunity to develop solutions aimed at prevention, treatment, and delivery of care for diabetes
In a new funding opportunity led by the Canadian Institutes for Health Research (CIHR), JDRF will partner with the federal agency to fund several new team grants that aim to uncover new mechanisms that control the onset and progression of diabetes and its related complications.
National Diabetes Awareness Month (NDAM) has officially come to an end, and we cannot thank you enough for your overwhelming support and participation. Here are some of the great initiatives you took part on that helped make this NDAM so special.
Beth Miller is a driven athlete with an indomitable spirit and a passion for life. At 16 years old, the Calgary resident has competed nationally in skiing and is currently a competitive rower who has represented her province twice at the National Rowing Championships – all while living wi...
ViaCyte Inc., a privately held regenerative medicine company, is seeking residents of Alberta to participate in a promising JDRF-funded clinical trial in Edmonton. The purpose of this research is to determine the safety, tolerability and efficacy of PEC-Direct™ (also known ...
JDRF has supported research in beta cell replacement for more than a decade, aiming to make a stem cell-based treatment for type 1 diabetes (T1D) a reality.
Sernova Corp., a regenerative medicine company based in London, ON., has shown in its JDRF-funded clinical trial that its cell replacement therapy, Cell PouchTM, can restore insulin production among people living with T1D.